Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Other Non-Current Liabilities (2021 - 2025)

Strata Critical Medical (SRTA) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 73.66% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 73.66% year-over-year, with the annual reading at $1.5 million for FY2025, 73.66% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.5 million at Strata Critical Medical, up from $42000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $42.2 million in Q3 2021, with the low at $42000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $9.5 million, with a median of $5.4 million recorded in 2023.
  • Peak annual rise in Other Non-Current Liabilities hit 106.49% in 2025, while the deepest fall reached 98.44% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $31.3 million in 2021, then tumbled by 77.38% to $7.1 million in 2022, then tumbled by 30.0% to $5.0 million in 2023, then grew by 17.14% to $5.8 million in 2024, then tumbled by 73.66% to $1.5 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.5 million, $42000.0, and $3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.